Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment
Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment
复制标题
DOI：
10.1111/apt.14380
复制
发表时间：
2018-01-01
影响因子：
7.6
通讯作者：
Hayashi, J.
中科院分区：
文献类型：
--
作者：
Ogawa, E.;Furusyo, N.;Hayashi, J.
随着直接作用抗病毒药物（DAAs）的发展，几乎所有慢性丙型肝炎病毒（HCV）感染患者都能实现持续病毒应答（SVR）。目的通过DAAs评估SVR患者（包括肝硬化或既往HCC患者）发生HCC的短期风险。方法：这项大规模、多中心队列研究纳入了1675例连续接受无干扰素索非布韦方案治疗达到SVR的患者，分为既往HCC组（n=152）和既往HCC组（n= 1523）。采用Kaplan-Meier法和Cox比例风险分析计算HCC累积发病率及相关因素。结果在随访期间（中位：17个月），46例（2.7%）患者发生HCC。非肝硬化组和肝硬化组的1年累积新发HCC率分别为0.4%和4.9% (log-rank检验：P
BackgroundWith the development of direct-acting anti-virals (DAAs), almost all patients with chronic hepatitis C virus (HCV) infection can achieve sustained viral response (SVR).AimTo evaluate the short-term risk of HCC among patients with SVR by DAAs, including those with cirrhosis or previous HCC.MethodsThis large-scale, multicentre cohort study included 1,675 consecutive patients who achieved SVR by treatment with interferon-free sofosbuvir-based regimens, divided into groups with (n=152) or without previous HCC (n=1,523). The Kaplan-Meier method and Cox proportional hazard analysis were used to calculate the cumulative HCC incidence and related factors of HCC.ResultsDuring the follow-up period (median: 17months), 46 (2.7%) patients developed HCC. The 1-year cumulative rates of de novo HCC were 0.4% and 4.9% for the noncirrhosis and cirrhosis groups respectively (log-rank test: P